This site is intended for healthcare professionals only.

This site is intended for healthcare professionals only.

Strapline if one is needed

Menu

Strapline if one is needed

About the program

This program aims to help physicians confidently implement the latest evidence-based strategies in lupus care. Developed in collaboration with leading experts Prof. Martin Aringer, Prof. Marta Mosca, and Dr. Johanna Mucke, the program addresses key challenges in management of SLE management wordwide.

Through a series of expert-led videos, we explore:

  • Updated EULAR 2023 guidelines and the rationale behind the treat-to-target approach
  • Standardization of disease activity measurement, including validated tools like LLDAS and DORIS
  • Barriers to implementation of best practices in real-world settings
  • The patient perspective, highlighting the emotional and physical burden of SLE and the importance of shared decision-making

Each module is available in video and podcast format, tailored to be mobile-friendly and bite-sized. A downloadable infographic summarizing key concepts and linking the video content provides a quick reference tool for clinical practice.

Updates, advances, and persistent unmet needs in SLE

An engaging introduction by Program Director Prof. Martin Aringer, highlighting best practices in lupus care and what learners can expect from the program.

Download infographic

Target audience

This independent educational program is suitable for Rheumatologists, Dermatologists, Nephrologists, Cardiologists, Neurologists, Gastroenterologists, and the wider global multidisciplinary team that manages SLE patients.

Planning committee

In addition to the expert faculty, Springer Health+ IME planners and staff include Kamran Ahmad and Jack Diamond. The planning committee have no financial relationships to disclose.

This program is aligned with Springer Medicine – an English-language, medical education platform provided by the Springer Nature Group. Springer Medicine supports doctors in their ongoing quest for optimal patient care, and delivers the latest evidence on new therapies, practice guidelines and news in easily digestible formats to keep healthcare professionals effortlessly up to date.

Learning objectives

Following completion of this independent educational program, learners will be able to:

  • Integrate the most recent guideline recommendations into practice including the treat-to-target approach
  • Utilize standardized disease activity measurement and validated tools
  • Explore and address challenges in implementing guidelines, including regional disparities
  • Address unmet patient needs and discuss how new treatments may help improve long-term outcomes
Close

Prof. Martin Aringer

Program Director
University Medical Center and Faculty of Medicine, Dresden, Germany

Martin Aringer, M.D., is Professor of Medicine, Chief of the Division of Rheumatology, and Director of the interdisciplinary University Center of Autoimmune and Rheumatic Entities (UCARE) at the University Medical Center and Faculty of Medicine, TU Dresden, Dresden, Germany. From 2003 to 2006, he was Associate Professor of Medicine at the Department of Rheumatology, Medical University of Vienna, Austria, where he also completed his training in Internal Medicine and Rheumatology under Prof. Josef Smolen. From 1997 to 1999, Dr. Aringer joined the laboratory of Dr. John O’Shea at the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, as a recipient of a Max Kade Postdoctoral Research Fellowship.

Dr. Aringer is a board member of the German Society of Rheumatology and a member of the American College of Rheumatology, the Austrian Society of Rheumatology, and the German and Austrian Societies of Internal Medicine. His main scientific focus is systemic lupus erythematosus (SLE). From 2014 to 2019, he served as the EULAR Steering Committee Co-Chair for the EULAR/ACR SLE Classification Criteria Project.

Disclosures

Honoraria or consultation fees: AbbVie, AstraZeneca, GSK, Johnson & Johnson, Roche, UCB

Close

Prof. Marta Mosca

Azienda Ospedaliera Universitaria Pisana, Italy

Marta Mosca, M.D., is Professor of Rheumatology at the University of Pisa and Head of the Rheumatology Unit at the Azienda Ospedaliera Universitaria Pisana, Italy. At the University of Pisa, Prof. Mosca also serves as Director of the Fellowship Training Program in Rheumatology. Since December 2016, she has been the Coordinator of the European Reference Network on Rare and Hereditary Connective and Musculoskeletal Diseases (RECONNET), which promotes better care for patients with rare, low-prevalence, and complex diseases, including systemic lupus erythematosus, antiphospholipid syndrome, Sjögren’s syndrome, and undifferentiated connective tissue diseases.

Prof. Mosca is a member of the Scientific Advisory Board of LUPUS EUROPE and, since November 2019, a member of the Systemic Lupus Erythematosus International Collaborating Clinics Group. She has contributed to the development of EULAR recommendations for the management of SLE, women’s health, and antiphospholipid syndrome in adults, and has coordinated the development of recommendations for monitoring SLE patients in clinical practice and observational studies. She was also a member of the EULAR/ACR Steering Committee for the development of classification criteria for SLE.

Disclosures

Participation in a company sponsored speaker bureau: AbbVie, AstraZeneca, Biogen, BMS, GSK, Lilly, Miltenyi, Novartis, Otsuka, Roche, UCB

Close

Dr. Johanna Mucke

Rheumazentrum Ruhrgebiet, Germany

Dr. Johanna Mucke is a distinguished rheumatologist based in Germany, currently serving as a consultant at the Rheumazentrum Ruhrgebiet. She earned her medical degree from Heidelberg University and completed her rheumatology training at Heinrich-Heine University Düsseldorf, where she was actively involved in both clinical practice and research from an early stage.

Dr. Mucke has contributed to the field of rheumatology through her research on systemic lupus erythematosus (SLE), with a particular focus on treat-to-target strategies and health-related quality of life. She coordinated and developed the first German guidelines for the management of SLE and has co-authored numerous publications, including studies on treat-to-target approaches, patient perspectives in SLE treatment, and future directions in rheumatology.

In addition to her research activities, Dr. Mucke is an engaged member of the German Society of Rheumatology and Clinical Immunology. She also serves as spokesperson for the German Commission for Gender Equity in Rheumatology, where she oversees projects related to gender medicine and equal opportunities.

Disclosures

Grants research/support: GSK
Honoraria or consultation fees:  AbbVie, AstraZeneca, Celltrion, GSK, Roche
Participation in a company sponsored speaker bureau: AbbVie, AstraZeneca, BMS, GSK, Novartis, Roche

Close

Prof. Martin Aringer

Program Director
University Medical Center and Faculty of Medicine, Dresden, Germany

Martin Aringer, M.D., is Professor of Medicine, Chief of the Division of Rheumatology, and Director of the interdisciplinary University Center of Autoimmune and Rheumatic Entities (UCARE) at the University Medical Center and Faculty of Medicine, TU Dresden, Dresden, Germany. From 2003 to 2006, he was Associate Professor of Medicine at the Department of Rheumatology, Medical University of Vienna, Austria, where he also completed his training in Internal Medicine and Rheumatology under Prof. Josef Smolen. From 1997 to 1999, Dr. Aringer joined the laboratory of Dr. John O’Shea at the National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, as a recipient of a Max Kade Postdoctoral Research Fellowship.

Dr. Aringer is a board member of the German Society of Rheumatology and a member of the American College of Rheumatology, the Austrian Society of Rheumatology, and the German and Austrian Societies of Internal Medicine. His main scientific focus is systemic lupus erythematosus (SLE). From 2014 to 2019, he served as the EULAR Steering Committee Co-Chair for the EULAR/ACR SLE Classification Criteria Project.

Disclosures

Honoraria or consultation fees: AbbVie, AstraZeneca, GSK, Johnson & Johnson, Roche, UCB

Close

Prof. Marta Mosca

Azienda Ospedaliera Universitaria Pisana, Italy

Marta Mosca, M.D., is Professor of Rheumatology at the University of Pisa and Head of the Rheumatology Unit at the Azienda Ospedaliera Universitaria Pisana, Italy. At the University of Pisa, Prof. Mosca also serves as Director of the Fellowship Training Program in Rheumatology. Since December 2016, she has been the Coordinator of the European Reference Network on Rare and Hereditary Connective and Musculoskeletal Diseases (RECONNET), which promotes better care for patients with rare, low-prevalence, and complex diseases, including systemic lupus erythematosus, antiphospholipid syndrome, Sjögren’s syndrome, and undifferentiated connective tissue diseases.

Prof. Mosca is a member of the Scientific Advisory Board of LUPUS EUROPE and, since November 2019, a member of the Systemic Lupus Erythematosus International Collaborating Clinics Group. She has contributed to the development of EULAR recommendations for the management of SLE, women’s health, and antiphospholipid syndrome in adults, and has coordinated the development of recommendations for monitoring SLE patients in clinical practice and observational studies. She was also a member of the EULAR/ACR Steering Committee for the development of classification criteria for SLE.

Disclosures

Participation in a company sponsored speaker bureau: AbbVie, AstraZeneca, Biogen, BMS, GSK, Lilly, Miltenyi, Novartis, Otsuka, Roche, UCB

Close

Dr. Johanna Mucke

Rheumazentrum Ruhrgebiet, Germany

Dr. Johanna Mucke is a distinguished rheumatologist based in Germany, currently serving as a consultant at the Rheumazentrum Ruhrgebiet. She earned her medical degree from Heidelberg University and completed her rheumatology training at Heinrich-Heine University Düsseldorf, where she was actively involved in both clinical practice and research from an early stage.

Dr. Mucke has contributed to the field of rheumatology through her research on systemic lupus erythematosus (SLE), with a particular focus on treat-to-target strategies and health-related quality of life. She coordinated and developed the first German guidelines for the management of SLE and has co-authored numerous publications, including studies on treat-to-target approaches, patient perspectives in SLE treatment, and future directions in rheumatology.

In addition to her research activities, Dr. Mucke is an engaged member of the German Society of Rheumatology and Clinical Immunology. She also serves as spokesperson for the German Commission for Gender Equity in Rheumatology, where she oversees projects related to gender medicine and equal opportunities.

Disclosures

Grants research/support: GSK
Honoraria or consultation fees:  AbbVie, AstraZeneca, Celltrion, GSK, Roche
Participation in a company sponsored speaker bureau: AbbVie, AstraZeneca, BMS, GSK, Novartis, Roche

Close
SLE: Translating Guidelines into Practice

Video discussions

Coming soon

Watch our panel of multidisciplinary experts explore key topics in lupus care through a series of video discussions. These sessions will provide practical insights into the latest advances in SLE, including guideline updates, disease activity measurement, implementation challenges, and the patient perspective.

Close
SLE: Translating Guidelines into Practice

Infographics

Coming soon

This concise infographic will summarize key learning points from the video discussions. Designed for quick reference and to serve as a practical tool to support clinical decision-making and patient education.

Close

Home